Fresenius today officially opened its new Innovation Center in Bad Homburg, Germany, marking a major milestone in strengthening research, development, and innovation in medical nutrition. The state-of-the-art laboratory, modern IT infrastructure and office facility accelerates new product development and drives innovation-led growth. In addition, it underscores Fresenius’ commitment to advancing patient care through science-based solutions and reinforces Europe as a key hub for healthcare.
“With the new Innovation Center, we are further embedding science in our Fresenius campus in Bad Homburg, strengthening collaboration and enabling fast, integrated decision-making. This is a clear commitment to our mission of improving patients’ lives through high-quality, accessible medical nutrition.” emphasized Sara Hennicken, CFO of Fresenius, who is also responsible for real estate within the group, and host of the opening ceremony.
Under the guiding theme A New Chapter for Medical Nutrition, the new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration, execution excellence, and innovation. By consolidating previously decentralized teams, Fresenius is creating a highly integrated environment to accelerate the development of next-generation nutritional therapies.
Nutrition as a cornerstone of patient health
Medical nutrition plays a critical and often underrecognized role in patient outcomes. Particularly for individuals suffering from malnutrition, a condition that can significantly affect recovery, hospital stays, and overall quality of life. The Innovation Center will focus on advancing enteral nutrition solutions, including the development of products within the company’s portfolio designed to meet the needs of vulnerable patient populations. In parallel, it drives the development of automated pumping systems for patient-specific compounding of sterile ingredients into bags for parenteral nutrition (PN) solutions. This enables the preparation of tailored micro- and macronutrient PN admixtures while reducing the need for manual additions.
“Innovation is at the heart of everything we do,” said Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability. “By combining scientific excellence with a deep understanding of patients’ needs, we are developing nutritional solutions that make a tangible difference in clinical practice and everyday life.”
At the center of the current strategic phase Rejuvenate is growth through innovation. The new facility embodies Fresenius’ broader ambition to translate scientific insights into practical healthcare solutions. As part of its long-term strategy, the company is investing in innovative platforms that bridge science and patient needs in line with #FutureFresenius.
With more than €50 million invested in the overall Bad Homburg campus in recent years, the Innovation Center adds to Fresenius’ ability to develop future-oriented therapies and contribute to resilient healthcare systems. It also demonstrates the continued commitment of Fresenius to its local-for-local approach not only when it comes to production but also in research and development.
Opening ceremony with distinguished participants
The opening ceremony brought together representatives from different functions, highlighting Fresenius leadership, research, and local government, including Sara Hennicken, CFO Fresenius, Alexander Hetjes, Mayor of Bad Homburg, Pierluigi Antonelli, CEO Fresenius Kabi, Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability, and José Mainou, SVP R&D Enteral Nutrition Fresenius Kabi. Their presence highlighted the significance of the new center for both the company and the regional innovation ecosystem.
“Bad Homburg and Fresenius have been closely connected for decades,” said Mayor Alexander Hetjes. “The company plays a particularly significant role in shaping our city economically and as an employer. At the same time, Bad Homburg offers an environment in which innovation, growth, and international talent find ideal conditions. It is a strong signal that Fresenius is investing here at the Bad Homburg site in research, development, and future viability.”
A strong signal for the future
The new Innovation Center reflects Fresenius’ commitment to patient-centricity, operational excellence, and technological leadership. By investing in cutting-edge infrastructure and interdisciplinary collaboration, the company is strengthening its ability to shape the future of medical nutrition, directly benefiting patients, healthcare systems, and society as a whole.
Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.
For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
New ready-to-use three-chamber bag parenteral nutrition solution strengthens Fresenius’ global clinical nutrition portfolio and reflect its commitment to patient centric innovation
Fresenius, a global healthcare company, today announced the European launch of the Pedismof® range, a new ready to use three chamber bag for pediatric parenteral nutrition. Developed by Fresenius Kabi, the introduction marks an important milestone within the clinical nutrition portfolio and aligns with the Company’s #FutureFresenius strategy to foster patient centric innovation, simplify care, and support patient access to essential therapies.
The range offers age-specific formulations for preterm and term neonates, infants, children, and adolescents, supporting standardized pediatric parenteral nutrition. It is the third product launch this year in the company’s clinical nutrition branch.
The three chamber bag combines glucose, amino acids with a balanced profile, and the lipid emulsion SMOFlipid®, which contains fish oil and omega 3 fatty acids. The formulation has been developed in line with established European pediatric nutrition guidelines1 and is available in multiple volumes to meet the nutritional requirements of most patients.
“The Pedismof® range is an example of how our clinical nutrition portfolio continues to evolve to address specific clinical and patient needs,” said Dr. Marc Alexander Mahl, President Pharma, Nutrition and Sustainability at Fresenius Kabi. “With age appropriate formulations and a ready to use design, we aim to support healthcare professionals in the delivery of neonatal and pediatric parenteral nutrition within established clinical frameworks.”
Just a few days ago – on June 2nd, Fresenius opened an Innovation Center in Germany focused specifically on clinical nutrition. The new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration and speed to continuously develop new products.
This launch is a further proof point of the company’s current strategy phase Rejuvenate by strengthening Fresenius’ clinical nutrition portfolio and underscores the Company’s focus on scalable, system relevant therapies that contribute to long term patient access and differentiated health outcomes.
Availability of Pedismof® range may vary by country and are subject to local regulatory approvals.
1Van Goudoever JB et al. Clin Nutr. 2018;37(6 Pt B):2315-2323. Lapillonne A et al. Clin Nutr. 2018;37(6 Pt B):2324-2336. Joosten K et al. Clin Nutr. 2018;37(6 Pt B):2309-2314. Mesotten D et al. Clin Nutr. 2018;37(6 Pt B):2337-2343. Mihatsch W et al. Clin Nutr. 2018;37(6 Pt B):2360-2365. Jochum F et al. Clin Nutr. 2018;37(6 Pt B):2344-2353.
Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.
For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
New ready-to-use three-chamber bag parenteral nutrition solution strengthens Fresenius’ global clinical nutrition portfolio and reflect its commitment to patient centric innovation
Fresenius, a global healthcare company, today announced the European launch of the Pedismof® range, a new ready to use three chamber bag for pediatric parenteral nutrition. Developed by Fresenius Kabi, the introduction marks an important milestone within the clinical nutrition portfolio and aligns with the Company’s #FutureFresenius strategy to foster patient centric innovation, simplify care, and support patient access to essential therapies.
The range offers age-specific formulations for preterm and term neonates, infants, children, and adolescents, supporting standardized pediatric parenteral nutrition. It is the third product launch this year in the company’s clinical nutrition branch.
The three chamber bag combines glucose, amino acids with a balanced profile, and the lipid emulsion SMOFlipid®, which contains fish oil and omega 3 fatty acids. The formulation has been developed in line with established European pediatric nutrition guidelines1 and is available in multiple volumes to meet the nutritional requirements of most patients.
“The Pedismof® range is an example of how our clinical nutrition portfolio continues to evolve to address specific clinical and patient needs,” said Dr. Marc Alexander Mahl, President Pharma, Nutrition and Sustainability at Fresenius Kabi. “With age appropriate formulations and a ready to use design, we aim to support healthcare professionals in the delivery of neonatal and pediatric parenteral nutrition within established clinical frameworks.”
Just a few days ago – on June 2nd, Fresenius opened an Innovation Center in Germany focused specifically on clinical nutrition. The new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration and speed to continuously develop new products.
This launch is a further proof point of the company’s current strategy phase Rejuvenate by strengthening Fresenius’ clinical nutrition portfolio and underscores the Company’s focus on scalable, system relevant therapies that contribute to long term patient access and differentiated health outcomes.
Availability of Pedismof® range may vary by country and are subject to local regulatory approvals.
1Van Goudoever JB et al. Clin Nutr. 2018;37(6 Pt B):2315-2323. Lapillonne A et al. Clin Nutr. 2018;37(6 Pt B):2324-2336. Joosten K et al. Clin Nutr. 2018;37(6 Pt B):2309-2314. Mesotten D et al. Clin Nutr. 2018;37(6 Pt B):2337-2343. Mihatsch W et al. Clin Nutr. 2018;37(6 Pt B):2360-2365. Jochum F et al. Clin Nutr. 2018;37(6 Pt B):2344-2353.
Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.
For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
Fresenius today officially opened its new Innovation Center in Bad Homburg, Germany, marking a major milestone in strengthening research, development, and innovation in medical nutrition. The state-of-the-art laboratory, modern IT infrastructure and office facility accelerates new product development and drives innovation-led growth. In addition, it underscores Fresenius’ commitment to advancing patient care through science-based solutions and reinforces Europe as a key hub for healthcare.
“With the new Innovation Center, we are further embedding science in our Fresenius campus in Bad Homburg, strengthening collaboration and enabling fast, integrated decision-making. This is a clear commitment to our mission of improving patients’ lives through high-quality, accessible medical nutrition.” emphasized Sara Hennicken, CFO of Fresenius, who is also responsible for real estate within the group, and host of the opening ceremony.
Under the guiding theme A New Chapter for Medical Nutrition, the new center will bring approximately 100 experts from multiple disciplines under one roof, fostering collaboration, execution excellence, and innovation. By consolidating previously decentralized teams, Fresenius is creating a highly integrated environment to accelerate the development of next-generation nutritional therapies.
Nutrition as a cornerstone of patient health
Medical nutrition plays a critical and often underrecognized role in patient outcomes. Particularly for individuals suffering from malnutrition, a condition that can significantly affect recovery, hospital stays, and overall quality of life. The Innovation Center will focus on advancing enteral nutrition solutions, including the development of products within the company’s portfolio designed to meet the needs of vulnerable patient populations. In parallel, it drives the development of automated pumping systems for patient-specific compounding of sterile ingredients into bags for parenteral nutrition (PN) solutions. This enables the preparation of tailored micro- and macronutrient PN admixtures while reducing the need for manual additions.
“Innovation is at the heart of everything we do,” said Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability. “By combining scientific excellence with a deep understanding of patients’ needs, we are developing nutritional solutions that make a tangible difference in clinical practice and everyday life.”
At the center of the current strategic phase Rejuvenate is growth through innovation. The new facility embodies Fresenius’ broader ambition to translate scientific insights into practical healthcare solutions. As part of its long-term strategy, the company is investing in innovative platforms that bridge science and patient needs in line with #FutureFresenius.
With more than €50 million invested in the overall Bad Homburg campus in recent years, the Innovation Center adds to Fresenius’ ability to develop future-oriented therapies and contribute to resilient healthcare systems. It also demonstrates the continued commitment of Fresenius to its local-for-local approach not only when it comes to production but also in research and development.
Opening ceremony with distinguished participants
The opening ceremony brought together representatives from different functions, highlighting Fresenius leadership, research, and local government, including Sara Hennicken, CFO Fresenius, Alexander Hetjes, Mayor of Bad Homburg, Pierluigi Antonelli, CEO Fresenius Kabi, Dr. Marc-Alexander Mahl, President Pharma, Nutrition and Sustainability, and José Mainou, SVP R&D Enteral Nutrition Fresenius Kabi. Their presence highlighted the significance of the new center for both the company and the regional innovation ecosystem.
“Bad Homburg and Fresenius have been closely connected for decades,” said Mayor Alexander Hetjes. “The company plays a particularly significant role in shaping our city economically and as an employer. At the same time, Bad Homburg offers an environment in which innovation, growth, and international talent find ideal conditions. It is a strong signal that Fresenius is investing here at the Bad Homburg site in research, development, and future viability.”
A strong signal for the future
The new Innovation Center reflects Fresenius’ commitment to patient-centricity, operational excellence, and technological leadership. By investing in cutting-edge infrastructure and interdisciplinary collaboration, the company is strengthening its ability to shape the future of medical nutrition, directly benefiting patients, healthcare systems, and society as a whole.
Fresenius (XFRA: FRE, OTCQX: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.
For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser
Chairman of the Supervisory Board: Wolfgang Kirsch
Fresenius Kabi, an operating company of Fresenius, has entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA designated essential medicine frequently at risk of shortage in the United States.
Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi manufactures the finished doses for hospitals and clinics across the country. With this initiative, Fresenius advances its local-for-local manufacturing strategy and supports national efforts to strengthen pharmaceutical security. The partnership reinforces the ambitions of #FutureFresenius as it expands Fresenius’ role as a leading global provider of lifesaving therapies, advancing resilient manufacturing that improves patient care and health-system stability.
Pending regulatory approvals, epinephrine produced through this collaboration could be available to U.S. hospitals in 2027.
Fresenius Kabi, an operating company of Fresenius, has entered a first-of-its-kind partnership with U.S. manufacturer Phlow Corp. to establish a fully domestic, end-to-end supply chain for Epinephrine Injection, USP — an FDA designated essential medicine frequently at risk of shortage in the United States.
Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi manufactures the finished doses for hospitals and clinics across the country. With this initiative, Fresenius advances its local-for-local manufacturing strategy and supports national efforts to strengthen pharmaceutical security. The partnership reinforces the ambitions of #FutureFresenius as it expands Fresenius’ role as a leading global provider of lifesaving therapies, advancing resilient manufacturing that improves patient care and health-system stability.
Pending regulatory approvals, epinephrine produced through this collaboration could be available to U.S. hospitals in 2027.
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments.
Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development.
The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation.
By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments.
Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development.
The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation.
By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.
mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.
The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.
This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.
mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.
The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.
This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.